nach oben

American Journal of Clinical Dermatology

Erschienen in:

28.11.2019 | Leading Article

Updates on Botulinum Neurotoxins in Dermatology

verfasst von: Edith Hanna, Kucy Pon

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Being the most popular non-surgical cosmetic procedure, botulinum neurotoxin (BoNT) injections are increasingly of interest to all cosmetic practitioners across the globe. This article serves to update readers on the new botulinum toxins that are currently in development or close to market in the USA and Canada, including daxibotulinumtoxin A, prabotulinumtoxin A, letibotulinumtoxin A, and botulinum toxin E. Despite having relatively similar characteristics and equivalent clinical efficacies, these neurotoxins manifest a multitude of unique potential advantages that will be explored in this review, including but not limited to a longer duration of action, the absence of animal-derived components or human albumin, and a rapid onset with short duration of action.

Lamanna C. The most poisonous poison. Science. 1959;130:763–72.CrossRef

Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924–7.PubMed

Carruthers J, Carruthers JA. Botulinum toxin use for glabellar wrinkles. Presented at the annual meeting of the American Society for Dermatologic Surgery, Orlando, Fla., March 13–17, 1991.

Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000;43(2):249–59.CrossRef

Jacobson MJ, Lin G, Tepp W, Dupuy J. Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222. Appl Environ Microbiol. 2011;77:4217–22.CrossRef

Won CH, Kim HK, Kim BJ, Kang H. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. Int J Dermatol. 2015;54(2):227–34.CrossRef

Beer KR, Shamban AT, Avelar RL, Gross JE. Efficacy and safety of prabotulinumtoxin A for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatol Surg. 2019;45:1381–93.CrossRef

Rzany BJ, Ascher B, Avelar RL, Bergdahl J. A Multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxin A and onabotulinumtoxin A for the treatment of moderate to severe glabellar lines in adult subjects. Aesthet Surg J. 2019.

Mishra M. FDA approves cheaper Botox rival to treat frown lines [Internet]. Reuters; [cited 2019 Feb 1]. https://reut.rs/2S8iv9q.

10.

Caprino M. Revance’s RT002 demonstrates unprecedented efficacy and duration in largest-ever aesthetic neuromodulator clinical program [Internet]. Revance Therapeutics, Inc. Revance Therapeutics, Inc.; [cited 2018, Dec 4]. https://investors.revance.com/news-releases/news-release-details/revances-rt002-demonstrates-unprecedented-efficacy-and-duration.

11.

Acquire Media. Revance reports results for RT001 topical phase 3 trial for lateral canthal lines [Internet]. Revance Therapeutics, Inc. Revance Therapeutics, Inc.; [cited 2016 June 13]. https://investors.revance.com/news-releases/news-release-details/revance-reports-results-rt001-topical-phase-3-trial-lateral.

12.

Solish N, Bertucci V, Humphrey S, Bhatia A. Two phase 3, randomized, double-blind, placebo-controlled, multicenter trials to evaluate the efficacy and safety of daxibotulinumtoxin A for injection to treat moderate to severe glabellar lines (SAKURA 1 and 2). J Am Acad Dermatol. 2018;79(3):AB306.

13.

Carruthers J, et al. Injectable daxibotulinumtoxin A for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxin A and placebo. Dermatol Surg. 2017;43:1321–31.CrossRef

14.

Guillen-Fabi S, Green JB, Liu Y, Rubio RG, Gallagher CJ. SAKURA-3, a large open-label safety study of daxibotulinumtoxin A for injection in glabellar lines. Toxicon. 2018;156(S1):S42.CrossRef

15.

Frevert J, Ahn KY, Park MY, Sunga O. Comparison of botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol. 2018;5(11):327–31.CrossRef

16.

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT03408236. Randomized, double-blind, active-controlled, multicenter, phase I/III clinical trial to evaluate the safety and efficacy of Botulax® as compared to Botox® in subject with moderate to severe crow’s feet lines; 2017 Sept 11 [First posted 2018 Jan 23]. https://www.clinicaltrials.gov/ct2/show/NCT03408236?term=botulax&rank=2.

17.

Rose A. Allergan to acquire Bonti adding new neurotoxin programs to medical aesthetics pipeline [Internet]. Allergan plc. Allergan plc.; [cited 2018 Sept 14]. https://www.allergan.com/news/news/thomson-reuters/allergan-to-acquire-bonti-adding-new-neurotoxin-pr.

18.

Yoelin SG, Dhawan SS, Vitarella D, Ahmad W, Hasan F, Abushakra S. Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study. Plast Reconstr Surg. 2018;142(6):847e–55e.CrossRef

19.

Rodrigues O. Bonti announces successful completion of phase 2a scar reduction clinical study [Internet]. Bonti. Bonti; [cited 2018 Aug 2]. https://www.biospace.com/article/releases/bonti-announces-successful-completion-of-phase-2a-scar-reduction-clinical-study/.

20.

Kim JE, Song EJ, Choi GS, Lew BL, Sim WY, Kang H. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plast Reconstr Surg. 2015;135(3):732–41.CrossRef

21.

Monheit GD, Nestor MS, Cohen J, Goldman MP. Evaluation of QM-1114, a novel ready-to-use liquid botulinum toxin, in aesthetic treatment of glabellar lines. 24th World Congress of Dermatology; 10-15 June 2019; Milan, Italy. https://www.wcd2019milan-dl.org/abstract-book/documents/late-breaking-abstracts/03-aesthetic-cosmetic-dermatology/evaluation-of-qm1114-a-novel-490.pdf.

22.

U.S. Food and Drug Administration. Myobloc^® (rimabotulinumtoxinB) injection [Internet]. Solstice Neurosciences, Inc. Solstice Neurosciences, Inc.; [cited 2009 July 31]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103846s5120lbl.pdf.

23.

Spencer JM, Gordon M, Goldberg DJ. Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis. J Cosmet Laser Ther. 2002;4(1):19–23.CrossRef

Titel: Updates on Botulinum Neurotoxins in Dermatology
verfasst von: Edith Hanna
Kucy Pon
Publikationsdatum: 28.11.2019
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 2/2020
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-019-00482-2

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Laser and Light-Based Treatment Modalities for the Management of Hidradenitis Suppurativa

Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

Diabetic Foot Ulcers: Appraising Standard of Care and Reviewing New Trends in Management

Retrospective Case Series on Risk Factors, Diagnosis and Treatment of Pseudomonas aeruginosa Nail Infections

Melasma Treatment: An Evidence-Based Review